← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Aqualung Therapeutics Corp.
Juno Beach, FL
$11,614,278
Total funding
9
Grants
Funding over time
peak $3.3M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,614,278 · 9
By mechanism
R42$8,122,276 · 4
R44$2,457,594 · 1
R41$1,034,408 · 4
Investigators at Aqualung Therapeutics Corp.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial$1,500,000
R44 · FY2023 · HL
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis$1,000,000
R42 · FY2021 · HL
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis$1,000,000
R42 · FY2022 · HL
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity$975,215
R42 · FY2023 · DK
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity$975,215
R42 · FY2024 · DK
A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial$957,594
R44 · FY2024 · HL
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension$809,000
R42 · FY2023 · HL
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension$808,999
R42 · FY2024 · HL
Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)$750,000
R42 · FY2020 · HL
Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)$750,000
R42 · FY2021 · HL
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis$300,001
R42 · FY2020 · HL
Targeting eNAMPT-TLR4 signaling with the novel ALT-100 mAb to slow IPF progression$284,699
R41 · FY2025 · HL
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity$269,233
R42 · FY2022 · DK
Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP)$265,096
R41 · FY2020 · HD
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension$259,613
R42 · FY2022 · HL
Targeting the P Selectin Pathway to Improve ARDS Survival$259,613
R41 · FY2022 · HL
The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients$225,000
R41 · FY2019 · HL
Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI)$225,000
R42 · FY2019 · HL